What distinguishes Semaglutide GLP-1, Wegovy, Mounjaro, and Ozempic from each other
The agency's language was unambiguous: "Retatrutide and Cagrilintide cannot be used in compounding under federal law." [3,5] The letters cited multiple FDCA violations, including Section 505(a) (unapproved new drug), Section 502(f)(1) (inadequate directions for use), and Sections 301(a) and 301(d) (introduction into interstate commerce of an unapproved drug)
These actions also present serious patient safety concerns by flooding the market with drugs that have not been reviewed by the FDA for safety, effectiveness and quality
Guiguer, E.L
How long should I take supplements while on GLP-1 medications
Obtaining retatrutide from unregulated online sources carries serious risks including contamination, mislabelling, and inaccurate dosing